NGF mimetics: GK & GTS seriesМиметики ФРН
A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.
What the studies found
Animal research · 2011
Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin
GK-2 reduced infarct area and improved neurological tests.
Study notes · methods, sources and limitations
Participants or model Rats with focal cerebral ischemia after middle cerebral artery occlusion
Important limitations
- Animal-only finding; human stroke benefit and safety are unestablished.
Bulletin of experimental biology and medicine · PMID 22462051 · Indexed abstract
Animal research · 2018
An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2
GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.
Study notes · methods, sources and limitations
Participants or model Rat transient middle cerebral artery occlusion; treatment-start timing experiment
Important limitations
- An animal treatment window cannot be used as a human treatment window. No human clinical outcome was measured.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457 · Indexed abstract
Animal research · 2015
Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.
GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.
Study notes · methods, sources and limitations
Participants or model HT-22 and PC12 cells; rat tail-flick experiments
Important limitations
- Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.
Journal of biomedical science · Indexed abstract
About NGF mimetics: GK & GTS series
Names in this research collection
GK-1 · GK-2 · GK-2a · GK-2b · GK-2c · GK-2d · GK-2e · GK-2w · GK-2f · GK-3 · GK-4 · GK-5 · GK-6 · GK-7 · GK-8 · GTS-113 · GTS-115 · TrkA
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2011
Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin
GK-2 reduced infarct area and improved neurological tests.
Study notes and original source
Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin
Seredenin SB, Silachev DN, Gudasheva TA, Pirogov YA, Isaev NK · Bulletin of experimental biology and medicine · PMID 22462051
GK-2 reduced infarct area and improved neurological tests.
- Population / setting
- Rats with focal cerebral ischemia after middle cerebral artery occlusion
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Animal-only finding; human stroke benefit and safety are unestablished.
Reviewed 2026-10-05.
Animal research · 2018
An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2
GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.
Study notes and original source
An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2
Seredenin SB, Povarnina PY, Gudasheva TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457
GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.
- Population / setting
- Rat transient middle cerebral artery occlusion; treatment-start timing experiment
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- An animal treatment window cannot be used as a human treatment window.
- No human clinical outcome was measured.
Reviewed 2026-10-05.
Animal research · 2015
Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.
GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.
Study notes and original source
Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.
Gudasheva TA, Povarnina PY, Antipova TA, Firsova YN, Konstantinopolsky MA, Seredenin SB · Journal of biomedical science
GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.
- Population / setting
- HT-22 and PC12 cells; rat tail-flick experiments
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Review of earlier studies · 2018
Novel Technologies for Dipeptide Drugs Design and their Implantation.
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study notes and original source
Novel Technologies for Dipeptide Drugs Design and their Implantation.
Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
- Population / setting
- Developer account of medicinal-chemistry programs
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Reviewed 2026-10-05.
Experiment described in a patent · 2017
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.
Study notes and original source
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
· Primary source linked above
The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.
Results and tables
Reported patent results
Findings described in words
Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.
Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.
Population or model Patent chemistry and preclinical examples
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| BDNF-model behavior | GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it | Different molecules; the unfavorable direction is retained |
| Candidate identity and viability | Some monomeric mimetics reduced neuronal viability; dimeric results were more favorable | Candidate-specific findings, not a class-wide clinical effect |
| Reporting conflict | GSB-104 descriptions and GK-2f structure mapping require reconciliation | No single pooled efficacy percentage inferred from inconsistent examples |
The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent chemistry and preclinical examples
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Patent proposals are not established clinical uses.
- Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.
Reviewed 2026-11-06.
Animal research · 2017
Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor
GTS-113 and GTS-115 were designed from NGF loop 3. GTS-115 showed cell protection and reduced infarct volume in a rat stroke model, but also induced hyperalgesia.
Study notes and original source
Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor
· Primary source linked above
GTS-113 and GTS-115 were designed from NGF loop 3. GTS-115 showed cell protection and reduced infarct volume in a rat stroke model, but also induced hyperalgesia.
- Population / setting
- Cultured cells and rat ischemia/pain models
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Publisher abstract reviewed; full methods pending.
- Animal efficacy and pain responses do not establish human benefit or safety.
Reviewed 2026-10-05.
Animal research · 2022
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
Study notes and original source
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
· Primary source linked above
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
- Population / setting
- Rodent forced-swim tests; comparison with cell-signaling results
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Behavioral proxies are not a clinical diagnosis or treatment outcome.
- Different schedules and models limit cross-compound comparisons.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗